Eloctate approval 'another incremental driver' for Biogen Idec
By Marie Powers
Tuesday, June 10, 2014
FDA approval of Biogen Idec's long-acting hemophilia A product upped the ante in the space, as Eloctate (antihemophilic factor [recombinant], Fc fusion protein) became the first recombinant hemophilia A therapy with prolonged circulation in the body and the only treatment indicated to reduce the frequency of bleeding episodes in the indication by offering prophylactic infusions every three to five days.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.